|
Market Closed -
Euronext Paris
11:55:00 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 0.3345 EUR | 0.00% |
|
-0.45% | +12.25% |
| 09-16 | Nicox to present NCX 470 data at a conference |  |
| 09-11 | Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 33.6M | - | - | - | ||
| 367B | |||||
| 66.89B | |||||
| 12.93B | |||||
| 7.54B | |||||
| 4.38B |
- Stock Market
- Stocks
- ALCOX Stock
- Charts Nicox SA
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
